States, Preemption, and Patented Drug Prices

States face severe budget pressures from patented brand-name drug costs, with single treatments sometimes exceeding half a billion dollars, forcing difficult trade-offs between medication access and funding for other critical services. The authors examine whether states can implement cost-containment and fair-pricing measures for patented drugs despite patent preemption doctrine, which limits state regulatory authority over federally-granted patent rights.